Literature DB >> 26139428

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

H Wu1,2, C Hu1, A Wang1,2, E L Weisberg3, W Wang1, C Chen1, Z Zhao1, K Yu1, J Liu1, J Wu1,2, A Nonami3, L Wang1, B Wang1, R M Stone3, S Liu3, J D Griffin3, J Liu1, Q Liu1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26139428      PMCID： PMC4987127          DOI： 10.1038/leu.2015.175

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Authors:  Zhengying Pan; Heleen Scheerens; Shyr-Jiann Li; Brian E Schultz; Paul A Sprengeler; L Chuck Burrill; Rohan V Mendonca; Michael D Sweeney; Keana C K Scott; Paul G Grothaus; Douglas A Jeffery; Jill M Spoerke; Lee A Honigberg; Peter R Young; Stacie A Dalrymple; James T Palmer
Journal:  ChemMedChem       Date:  2007-01       Impact factor: 3.466

2.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

3.  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Woyach; Engin Bojnik; Amy S Ruppert; Matthew R Stefanovski; Virginia M Goettl; Kelly A Smucker; Lisa L Smith; Jason A Dubovsky; William H Towns; Jessica MacMurray; Bonnie K Harrington; Melanie E Davis; Stefania Gobessi; Luca Laurenti; Betty Y Chang; Joseph J Buggy; Dimitar G Efremov; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

4.  JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Authors:  H Quentmeier; R A F MacLeod; M Zaborski; H G Drexler
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

5.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

6.  Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Authors:  Erica K Evans; Richland Tester; Sharon Aslanian; Russell Karp; Michael Sheets; Matthew T Labenski; Steven R Witowski; Heather Lounsbury; Prasoon Chaturvedi; Hormoz Mazdiyasni; Zhendong Zhu; Mariana Nacht; Martin I Freed; Russell C Petter; Alex Dubrovskiy; Juswinder Singh; William F Westlin
Journal:  J Pharmacol Exp Ther       Date:  2013-05-24       Impact factor: 4.030

7.  Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Authors:  Wen Gao; Michael Wang; Li Wang; Haibo Lu; Shuhong Wu; Bingbing Dai; Zhishuo Ou; Liang Zhang; John V Heymach; Kathryn A Gold; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Authors:  Stuart A Rushworth; Megan Y Murray; Lyubov Zaitseva; Kristian M Bowles; David J MacEwan
Journal:  Blood       Date:  2013-12-04       Impact factor: 22.113
View more
  11 in total

1.  Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.

Authors:  Lara Rizzotto; Tzung-Huei Lai; Arianna Bottoni; Jennifer A Woyach; Rosa Lapalombella; Clara D Bloomfield; John C Byrd; Deepa Sampath
Journal:  Leuk Lymphoma       Date:  2017-09-18

2.  MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

Authors:  B Xu; Y Zhao; X Wang; P Gong; W Ge
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

3.  Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.

Authors:  H Wu; A Wang; Z Qi; X Li; C Chen; K Yu; F Zou; C Hu; W Wang; Z Zhao; J Wu; J Liu; X Liu; L Wang; W Wang; S Zhang; R M Stone; I A Galinsky; J D Griffin; D Weinstock; A Christodoulou; H Wang; Y Shen; Z Zhai; E L Weisberg; J Liu; Q Liu
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

Review 4.  FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Authors:  Maria Larrosa-Garcia; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2017-06       Impact factor: 6.261

5.  Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.

Authors:  Lianne E Rotin; Marcela Gronda; Neil MacLean; Rose Hurren; XiaoMing Wang; Feng-Hsu Lin; Jeff Wrana; Alessandro Datti; Dwayne L Barber; Mark D Minden; Malik Slassi; Aaron D Schimmer
Journal:  Oncotarget       Date:  2016-01-19

6.  The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.

Authors:  Xia Li; Xiufeng Yin; Huafeng Wang; Jiansong Huang; Mengxia Yu; Zhixin Ma; Chenying Li; Yile Zhou; Xiao Yan; ShuJuan Huang; Jie Jin
Journal:  Oncotarget       Date:  2017-02-21

7.  Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.

Authors:  Ami B Patel; Anthony D Pomicter; Dongqing Yan; Anna M Eiring; Orlando Antelope; Jonathan A Schumacher; Todd W Kelley; Srinivas K Tantravahi; Tibor J Kovacsovics; Paul J Shami; Thomas O'Hare; Michael W Deininger
Journal:  Leukemia       Date:  2020-05-14       Impact factor: 11.528

Review 8.  B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.

Authors:  Tanyaporn Pattarabanjird; Cynthia Li; Coleen McNamara
Journal:  JACC Basic Transl Sci       Date:  2021-06-28

9.  Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.

Authors:  S C Nimmagadda; S Frey; B Edelmann; C Hellmich; L Zaitseva; G M König; E Kostenis; K M Bowles; T Fischer
Journal:  Leukemia       Date:  2017-11-07       Impact factor: 11.528

10.  Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.

Authors:  Shujuan Huang; Chenying Li; Xiang Zhang; Jiajia Pan; Fenglin Li; Yunfei Lv; Jingwen Huang; Qing Ling; Wenle Ye; Shihui Mao; Xin Huang; Jie Jin
Journal:  Mol Oncol       Date:  2020-07-03       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.